



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday March 18, 2026

Details of +securities that have ceased

ASX +security code	Security description	Number of +securities that have ceased	The +securities have ceased due to	Date of cessation
TLXAO	SHARE APPRECIATION RIGHTS	1,014,318	Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied	16/03/2026

Refer to next page for full details of the announcement



Part 1 - Announcement Details

1.1 Name of +Entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) provide the following information about our issued capital.

1.2 Registered Number Type

ACN

Registration Number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

18/3/2026

For personal use only



Part 2 - Details of +equity securities or +debt securities that have ceased

ASX +Security Code and Description

TLXAO : SHARE APPRECIATION RIGHTS

Unquoted +equity securities that have ceased

Number of securities that have ceased

1,014,318

Reason for cessation

Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied

Date of cessation

16/3/2026

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?

Share Appreciation Rights under Telix's Equity Incentive Plan, lapsed because the conditions have not been met, including lapse of 20,045 Performance Share Appreciation Rights granted to the MD & CEO following shareholder approval at the AGM held 24 May 2023 as a result of testing of the 2023 PSARs grant.



Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,891,048

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,220,004
TLXAO : SHARE APPRECIATION RIGHTS	14,084,553
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	208,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,319,130
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.